Internal Medicine, Allergy & Immunology · Houston, TX
NPI
1568692820
Since 2009
Specialty
Internal Medicine, Allergy & Immunology
Code 207RA0201X
Group practices
3
Medicare group memberships
Hospitals
0
Hospital affiliations
17070 Red Oak Dr Ste 105
Houston, TX, 77090
Phone (832) 648-7779
Groups this clinician bills Medicare through
Medicare paid, 2024
$247K
24,368 services
Medicare patients, 2024
112
Average age 68
Drug cost, 2024
$1.5M
2,018 prescriptions
Company payments, 2025
$863
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Muhammad A Imran was code J0897 (injection, denosumab, 1 mg), 1,560 times for 18 patients. In total Muhammad A Imran billed 24,368 services in 94 codes, and Medicare paid $247K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-10-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 1,560 | 18 | $19.89 | $31K |
| 95004 Test - Miscellaneous | Office | 1,380 | 14 | $2.98 | $4,118 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 445 | 49 | $0.75 | $332 |
| 99214 Office E&M - Established | Office | 304 | 99 | $93.17 | $28K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 240 | 30 | $47.77 | $11K |
| J1885 Injection, ketorolac tromethamine, per 15 mg | Office | 184 | 26 | $0.48 | $89.13 |
| 96372 Injection Administration | Office | 150 | 42 | $10.70 | $1,604 |
| 99213 Office E&M - Established | Office | 122 | 44 | $68.75 | $8,387 |
| 96401 Chemotherapy Administration | Office | 111 | 25 | $55.12 | $6,118 |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 107 | 28 | $36.51 | $3,906 |
| 73560 X-ray - Lower Extremity | Office | 59 | 30 | $24.42 | $1,441 |
| 85025 Blood Count | Office | 56 | 49 | $7.61 | $426 |
| 73120 X-ray - Upper Extremity | Office | 52 | 27 | $24.10 | $1,253 |
| 94375 Pulmonary Function Testing | Office | 51 | 24 | $27.10 | $1,382 |
| 80053 Clinical Chemistry | Office | 51 | 44 | $10.35 | $528 |
By year: 2022 $217K for 8,616 services; 2023 $320K for 14,132 services; 2024 $247K for 24,368 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 56 | 49 | $7.61 | $426 |
| 80053 Clinical Chemistry | 51 | 44 | $10.35 | $528 |
| 84443 Clinical Chemistry | 19 | 18 | $16.46 | $313 |
| 82306 Clinical Chemistry | 17 | 16 | $29.01 | $493 |
| 82607 Clinical Chemistry | 12 | 12 | $14.78 | $177 |
Medicare prescription drug claims, 2024
In 2024, the drug Muhammad A Imran prescribed most often to Medicare patients was Prednisone, with 306 prescriptions and refills. In total Muhammad A Imran wrote 2,018 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 306 | 405 | 149 | $976 |
| Hydroxychloroquine Sulfate Generic | 136 | 330 | 64 | $4,341 |
| Pregabalin Generic | 109 | 123 | 24 | $2,452 |
| Gabapentin Generic | 104 | 204 | 52 | $1,229 |
| Tizanidine Hcl Generic | 93 | 161 | 46 | $592 |
| Methotrexate Methotrexate Sodium | 76 | 181 | 40 | $1,703 |
| Montelukast Sodium Generic | 74 | 180 | 34 | $535 |
| Fluticasone Propionate Generic | 70 | 115 | 50 | $802 |
| Ipratropium Bromide Generic | 63 | 79 | 31 | $1,376 |
| Duloxetine Hcl Generic | 55 | 122 | 27 | $1,569 |
| Lidocaine Generic | 55 | 57 | 20 | $4,509 |
| Celecoxib Generic | 42 | 56 | 24 | $607 |
| Orencia Abatacept/Maltose | 40 | 40 | Under 11 | $166K |
| Inflectra Infliximab-Dyyb | 39 | 65 | Under 11 | $141K |
| Diclofenac Potassium Generic | 36 | 37 | 24 | $363 |
Brand drugs: - claims; generic drugs: 1,613 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Muhammad A Imran $863 ($863 in general payments such as food, travel and fees) from 13 companies. The largest payer was Amgen Inc. with $120.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 7 | $120 |
| Regeneron Healthcare Solutions, Inc. REGN | 3 | $97.23 |
| GlaxoSmithKline, LLC. GSK | 5 | $92.8 |
| Mallinckrodt Hospital Products Inc. | 3 | $90.03 |
| UCB, Inc. UCB.BR | 3 | $79.06 |
| ARS Pharmaceuticals Operations, Inc. SPRY | 4 | $78.44 |
| Janssen Biotech, Inc. JNJ | 1 | $77.99 |
| ANI Pharmaceuticals, Inc. ANIP | 3 | $60.09 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $54.22 |
| Optinose US, Inc. | 2 | $43.14 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.